Core Insights - Nautilus Biotechnology, Inc. is set to report its financial results for Q4 and the full year of 2024 on February 27, 2025, before market open [1] - A conference call will be held to discuss the results, business developments, and outlook, starting at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time [2] - Nautilus is a development stage life sciences company focused on creating a platform technology for protein analysis, aiming to advance the field of proteomics and improve access to proteomic data [3]

Financial Performance - The net loss for the nine months ended September 30, 2024 was $53,186 thousand, compared to a net loss of $46,651 thousand for the same period in 2023, representing an increase of approximately 14%[14]. - For the three months ended September 30, 2024, Nautilus Biotechnology reported a net loss of $16.446 million, compared to a net loss of $15.878 million for the same period in 2023, reflecting an increase in losses of approximately 3.6%[18]. - The company reported total operating expenses of $61,496 thousand for the nine months ended September 30, 2024, compared to $56,151 thousand for the same period in 2023, an increase of approximately 9.5%[14]. - Cash used in operating activities for the nine months ended September 30, 2024, was $44.836 million, compared to $37.811 million for the same period in 2023, indicating an 18.4% increase in cash outflow[22]. Assets and Liabilities - Total current assets decreased from $176,837 thousand as of December 31, 2023 to $144,205 thousand as of September 30, 2024, a decline of approximately 18.4%[11]. - Cash and cash equivalents decreased from $19,397 thousand as of December 31, 2023 to $4,409 thousand as of September 30, 2024, a decrease of approximately 77.3%[11]. - Total liabilities decreased from $40,212 thousand as of December 31, 2023 to $36,270 thousand as of September 30, 2024, a reduction of approximately 9.7%[12]. - The company’s total stockholders' equity decreased from $265,353 thousand as of December 31, 2023 to $223,434 thousand as of September 30, 2024, a decline of approximately 15.8%[13]. Accumulated Deficit - The company’s accumulated deficit increased from $202,239 thousand as of December 31, 2023 to $255,425 thousand as of September 30, 2024, an increase of approximately 26.3%[13]. - The company had an accumulated deficit of $255.425 million as of September 30, 2024, compared to $185.215 million as of September 30, 2023, representing an increase in the deficit of approximately 37.8%[19]. Research and Development - Research and development expenses for the three months ended September 30, 2024 were $12,288 thousand, compared to $11,996 thousand for the same period in 2023, reflecting an increase of 2.4%[14]. - The company has been focused on research and development activities related to its proteomics platform since its incorporation in 2016[24]. Stock and Equity - The weighted-average shares used in computing net loss per share attributable to common stockholders for the nine months ended September 30, 2024 was 125,302,440, compared to 124,896,975 for the same period in 2023[14]. - The company issued 367,813 shares of common stock upon the exercise of vested stock options during the nine months ended September 30, 2024, raising $415,000[22]. - The total additional paid-in capital increased to $478.115 million as of September 30, 2024, from $464.509 million as of September 30, 2023, marking an increase of approximately 2.6%[19]. - The total potentially dilutive common share equivalents increased to 17,484,880 from 14,710,602 year-over-year[84]. Cash and Investments - Nautilus Biotechnology's cash, cash equivalents, and restricted cash at the end of the period on September 30, 2024, was $5.411 million, down from $75.106 million at the end of September 30, 2023, a decrease of approximately 92.8%[22]. - As of September 30, 2024, the company had cash, cash equivalents, and investments totaling $221.2 million[139]. - The carrying amount of cash equivalents approximates fair value due to short maturities of these instruments[139]. Risks and Future Financing - The company may require additional equity or debt financing in the future, depending on growth rate and research and development spending[30]. - The company is subject to risks similar to pre-clinical stage companies in the biopharmaceutical industry, including dependence on key individuals and the need for adequate financing[34]. - The company is exposed to inflation risk, which has impacted labor and goods costs, potentially affecting future operational expenses[140]. Accounting and Reporting - The company is evaluating the impact of new accounting standards on its consolidated financial statements, including ASU 2023-07 and ASU 2023-09[50][51]. - The company’s estimates and assumptions in financial reporting may differ from actual results, impacting future financial statements[31]. - The company had no income tax expense or benefit recognized for the three and nine months ended September 30, 2024, due to a full valuation allowance against deferred tax assets[61].

NAUTILUS" BIOTECHNOLOGY Delivering on the Promise of the Proteome OCTOBER 29, 2024 Safe harbor This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the size and growth of the protein analysis market; Nautilus Biotechnology's anticipated total addressable market; the performance, value and enabling nature of Nautilus Biotechnology's proteomics and pr ...

Financial Performance - Net loss for Q3 2024 was $16.4 million, compared to a net loss of $15.9 million in Q3 2023[4] - Operating expenses for Q3 2024 were $19.1 million, flat compared to Q3 2023[3] - The company reported a net cash used in operating activities of $44.8 million for the nine months ended September 30, 2024, compared to $37.8 million for the same period in 2023[15] Cash and Investments - Cash, cash equivalents, and investments totaled $221.2 million as of September 30, 2024[4] - Cash, cash equivalents, and restricted cash at the end of the period were $5.4 million, down from $75.1 million at the end of Q3 2023[15] Expenses - Research and development expenses for Q3 2024 were $12.3 million, up from $12.0 million in Q3 2023[13] - General and administrative expenses for Q3 2024 were $6.8 million, down from $7.1 million in Q3 2023[13] Assets and Liabilities - Total assets decreased to $259.7 million as of September 30, 2024, from $305.6 million at the end of 2023[11] - Total liabilities decreased to $36.3 million as of September 30, 2024, from $40.2 million at the end of 2023[11] Strategic Focus - The company is focused on advancing its single-molecule proteome analysis platform, which is expected to enhance research capabilities in proteomics[2]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 98-1541723 ...

Exhibit 99.1 Nautilus Biotechnology Reports Second Quarter 2024 Financial Results SEATTLE, WA, July 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single- molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. "In Q2, we saw continued progress against core development goals for each of the components of our platform," said Sujal Patel, CEO of Nautilus. "We believe we are pioneering a fundamentally new a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Address of principal executive offices) (Zip Code) (206) 333-2001 (Regis ...

Exhibit 99.1 Nautilus Biotechnology Reports First Quarter 2024 Financial Results SEATTLE, WA, April 30, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. "We continued to make solid progress against our core development goals in Q1," said Sujal Patel, CEO of Nautilus. "We remain incredibly focused on increasing the scale, stability, and reproducibil ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________________________________________________________ FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission file number 001-39434 NAUTILUS BIOTECHNOLOGY, INC. (Exact nam ...

Exhibit 99.1 Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results SEATTLE, WA, February 28, 2024 – Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or "Nautilus"), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. "2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2 ...